Prema Maria Mertz

Array ( [id] => 18497400 [patent_doc_number] => 20230220030 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-07-13 [patent_title] => HETERODIMERIC PROTEINS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/155218 [patent_app_country] => US [patent_app_date] => 2023-01-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 38767 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18155218 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20401272 [patent_doc_number] => 12491232 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-12-09 [patent_title] => Low dose IL-2 for treating autoimmune-related or inflammatory disorders [patent_app_type] => utility [patent_app_number] => 18/151383 [patent_app_country] => US [patent_app_date] => 2023-01-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 9 [patent_no_of_words] => 9083 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 70 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18151383 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20357573 [patent_doc_number] => 12473560 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-11-18 [patent_title] => Antigen binding molecules targeting SARS-CoV-2 [patent_app_type] => utility [patent_app_number] => 18/151088 [patent_app_country] => US [patent_app_date] => 2023-01-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 17592 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 124 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18151088 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18351423 [patent_doc_number] => 20230139534 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-05-04 [patent_title] => METHODS OF TREATING GRAFT VERSUS HOST DISEASE USING IL-2 MUTEINS [patent_app_type] => utility [patent_app_number] => 18/068970 [patent_app_country] => US [patent_app_date] => 2022-12-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5605 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 32 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18068970 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18673113 [patent_doc_number] => 20230310591 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-05 [patent_title] => Vaccine Boost Methods and Compositions [patent_app_type] => utility [patent_app_number] => 18/062817 [patent_app_country] => US [patent_app_date] => 2022-12-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13228 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18062817 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18692578 [patent_doc_number] => 20230322879 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-12 [patent_title] => CYTOKINE-BASED MULTI-EPITOPE PROTEIN FOR BINDING TO CCR7-POSITIVE CELLS [patent_app_type] => utility [patent_app_number] => 18/073599 [patent_app_country] => US [patent_app_date] => 2022-12-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9408 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 79 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18073599 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18852724 [patent_doc_number] => 11850276 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-12-26 [patent_title] => Interleukin-18 variants and methods of use [patent_app_type] => utility [patent_app_number] => 18/060816 [patent_app_country] => US [patent_app_date] => 2022-12-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 56 [patent_figures_cnt] => 83 [patent_no_of_words] => 59081 [patent_no_of_claims] => 31 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 402 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18060816 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18321534 [patent_doc_number] => 20230119662 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-04-20 [patent_title] => ANTI-VEGF PROTEIN COMPOSITIONS AND METHODS FOR PRODUCING THE SAME [patent_app_type] => utility [patent_app_number] => 17/994223 [patent_app_country] => US [patent_app_date] => 2022-11-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 67611 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 191 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17994223 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18522959 [patent_doc_number] => 20230233609 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-07-27 [patent_title] => THERAPEUTIC PROTEIN COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME [patent_app_type] => utility [patent_app_number] => 18/053203 [patent_app_country] => US [patent_app_date] => 2022-11-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15615 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18053203 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18529932 [patent_doc_number] => 20230234999 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-07-27 [patent_title] => PRODUCTION OF RECOMBINANT LUBRICIN [patent_app_type] => utility [patent_app_number] => 17/975572 [patent_app_country] => US [patent_app_date] => 2022-10-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10643 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17975572 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20492642 [patent_doc_number] => 12534505 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-01-27 [patent_title] => Activatable interleukin-2 polypeptides and methods of use thereof [patent_app_type] => utility [patent_app_number] => 18/045160 [patent_app_country] => US [patent_app_date] => 2022-10-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 48 [patent_figures_cnt] => 95 [patent_no_of_words] => 30134 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 309 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18045160 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18391384 [patent_doc_number] => 20230159602 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-05-25 [patent_title] => ENGINEERED OPTIMIZED CYTOKINE COMPOSITIONS [patent_app_type] => utility [patent_app_number] => 17/937005 [patent_app_country] => US [patent_app_date] => 2022-09-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8354 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 48 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17937005 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18391429 [patent_doc_number] => 20230159647 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-05-25 [patent_title] => METHODS FOR TREATING ALLERGY AND ENHANCING ALLERGEN-SPECIFIC IMMUNOTHERAPY BY ADMINISTERING AN IL-4R INHIBITOR [patent_app_type] => utility [patent_app_number] => 17/935003 [patent_app_country] => US [patent_app_date] => 2022-09-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9283 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17935003 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18212131 [patent_doc_number] => 20230058395 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-02-23 [patent_title] => METHODS FOR TREATING ATOPIC DERMATITIS BY ADMINISTERING AN IL-4R ANTAGONIST [patent_app_type] => utility [patent_app_number] => 17/951987 [patent_app_country] => US [patent_app_date] => 2022-09-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 53739 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 229 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17951987 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19601097 [patent_doc_number] => 20240391977 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-11-28 [patent_title] => TPO MIMETIC FUSION PROTEINS AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 18/694818 [patent_app_country] => US [patent_app_date] => 2022-09-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20225 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -36 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18694818 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18294531 [patent_doc_number] => 20230104217 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-04-06 [patent_title] => FUSION PROTEIN COMPRISING IL-2 PROTEIN AND CD80 PROTEIN, AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/948894 [patent_app_country] => US [patent_app_date] => 2022-09-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25680 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 103 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17948894 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20129200 [patent_doc_number] => 12371502 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-07-29 [patent_title] => Antibodies directed against CD127 [patent_app_type] => utility [patent_app_number] => 17/941885 [patent_app_country] => US [patent_app_date] => 2022-09-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 28 [patent_figures_cnt] => 28 [patent_no_of_words] => 30731 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 158 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17941885 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20771523 [patent_doc_number] => 12655183 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-06-16 [patent_title] => Methods and compositions for treating and/or preventing a disease or disorder associated with abnormal level and/or activity of the IFP35 family of proteins [patent_app_type] => utility [patent_app_number] => 17/930635 [patent_app_country] => US [patent_app_date] => 2022-09-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 58 [patent_figures_cnt] => 126 [patent_no_of_words] => 32102 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 229 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17930635 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20157015 [patent_doc_number] => 12383613 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-08-12 [patent_title] => Recombinant antigen and method of making the same, isolated polynucleotide of porcine reproductive and respiratory syndrome virus (PRRSV) and immunogenic composition including the same [patent_app_type] => utility [patent_app_number] => 17/930168 [patent_app_country] => US [patent_app_date] => 2022-09-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 13 [patent_no_of_words] => 0 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 37 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17930168 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18537538 [patent_doc_number] => 20230242636 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-03 [patent_title] => MONOCLONAL ANTIBODIES TARGETED TO HUMAN TAXILIN ALPHA AND METHODS FOR USE OF SAME [patent_app_type] => utility [patent_app_number] => 17/930028 [patent_app_country] => US [patent_app_date] => 2022-09-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4046 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -3 [patent_words_short_claim] => 32 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17930028 [rel_patent_id] =>[rel_patent_doc_number] =>)